Percutaneous management of pyogenic spondylodiscitis using absorbable antibiotic carrier (STIMULAN®): preliminary results from a single-center study.

IF 2.6 3区医学 Q2 CLINICAL NEUROLOGY

Neuroradiology Pub Date : 2025-08-01 Epub Date: 2025-06-14 DOI:10.1007/s00234-025-03676-0

Matteo Bellini, Joshua Adam Hirsch, Stefano Marcia, Ernesto Piane, Margherita Di Stefano, Vittoria Balletta, Marzio Formisano, Chiara Zini

{"title":"Percutaneous management of pyogenic spondylodiscitis using absorbable antibiotic carrier (STIMULAN®): preliminary results from a single-center study.","authors":"Matteo Bellini, Joshua Adam Hirsch, Stefano Marcia, Ernesto Piane, Margherita Di Stefano, Vittoria Balletta, Marzio Formisano, Chiara Zini","doi":"10.1007/s00234-025-03676-0","DOIUrl":null,"url":null,"abstract":"Purpose: This study evaluates the feasibility of using a fully resorbable antibiotic carrier (STIMULAN®, Rapid Cure, Biocomposites Ltd, UK) for the targeted treatment of spondylodiscitis (SD) through percutaneous injection directly into the infection site.Material and methods: Between 2022 and 2024, 13 patients diagnosed with SD underwent percutaneous osteo-discal biopsy followed by intradiscal and intravertebral injection of tailored antibiotic-loaded calcium sulfate paste. Clinical assessments (VAS), laboratory markers (CRP and leukocyte counts), and MRI imaging were used to monitor outcomes up to 12 months.Results: The procedure achieved 100% technical success with no major complications. All patients showed significant symptom relief, with VAS scores decreasing from 8.2 at baseline to 3.5 at 12 months. Inflammatory markers improved consistently, particularly CRP, which dropped from 7.35 to 0.23 (p ≈ 0.00005).Conclusions: These findings suggest that STIMULAN® enables safe, effective local antibiotic delivery in SD, with meaningful clinical and biomarker improvements. Nonetheless, larger multicenter studies are needed to validate these preliminary results and assess long-term efficacy.","PeriodicalId":19422,"journal":{"name":"Neuroradiology","volume":" ","pages":"2233-2237"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroradiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00234-025-03676-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study evaluates the feasibility of using a fully resorbable antibiotic carrier (STIMULAN®, Rapid Cure, Biocomposites Ltd, UK) for the targeted treatment of spondylodiscitis (SD) through percutaneous injection directly into the infection site.

Material and methods: Between 2022 and 2024, 13 patients diagnosed with SD underwent percutaneous osteo-discal biopsy followed by intradiscal and intravertebral injection of tailored antibiotic-loaded calcium sulfate paste. Clinical assessments (VAS), laboratory markers (CRP and leukocyte counts), and MRI imaging were used to monitor outcomes up to 12 months.

Results: The procedure achieved 100% technical success with no major complications. All patients showed significant symptom relief, with VAS scores decreasing from 8.2 at baseline to 3.5 at 12 months. Inflammatory markers improved consistently, particularly CRP, which dropped from 7.35 to 0.23 (p ≈ 0.00005).

Conclusions: These findings suggest that STIMULAN® enables safe, effective local antibiotic delivery in SD, with meaningful clinical and biomarker improvements. Nonetheless, larger multicenter studies are needed to validate these preliminary results and assess long-term efficacy.

查看原文本刊更多论文

使用可吸收抗生素载体（刺激an®）经皮治疗化脓性脊椎炎：一项单中心研究的初步结果。

目的：本研究评估使用完全可吸收的抗生素载体（刺激an®，Rapid Cure, Biocomposites Ltd， UK）通过经皮直接注射到感染部位靶向治疗脊椎炎（SD）的可行性。材料和方法：在2022年至2024年期间，13名诊断为SD的患者接受了经皮骨椎间盘活检，然后在椎间盘内和椎体内注射了定制的抗生素硫酸钙膏。使用临床评估（VAS）、实验室标志物（CRP和白细胞计数）和MRI成像监测长达12个月的预后。结果：手术技术成功率100%，无重大并发症。所有患者均表现出明显的症状缓解，VAS评分从基线时的8.2降至12个月时的3.5。炎症指标持续改善，尤其是CRP，从7.35降至0.23 （p≈0.00005）。结论：这些研究结果表明，在SD患者中，刺激an®能够安全、有效地局部给药，并具有显著的临床和生物标志物改善。然而，需要更大规模的多中心研究来验证这些初步结果并评估长期疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuroradiology 医学-核医学

CiteScore

5.30

自引率

3.60%

发文量

214

审稿时长

4-8 weeks

期刊介绍： Neuroradiology aims to provide state-of-the-art medical and scientific information in the fields of Neuroradiology, Neurosciences, Neurology, Psychiatry, Neurosurgery, and related medical specialities. Neuroradiology as the official Journal of the European Society of Neuroradiology receives submissions from all parts of the world and publishes peer-reviewed original research, comprehensive reviews, educational papers, opinion papers, and short reports on exceptional clinical observations and new technical developments in the field of Neuroimaging and Neurointervention. The journal has subsections for Diagnostic and Interventional Neuroradiology, Advanced Neuroimaging, Paediatric Neuroradiology, Head-Neck-ENT Radiology, Spine Neuroradiology, and for submissions from Japan. Neuroradiology aims to provide new knowledge about and insights into the function and pathology of the human nervous system that may help to better diagnose and treat nervous system diseases. Neuroradiology is a member of the Committee on Publication Ethics (COPE) and follows the COPE core practices. Neuroradiology prefers articles that are free of bias, self-critical regarding limitations, transparent and clear in describing study participants, methods, and statistics, and short in presenting results. Before peer-review all submissions are automatically checked by iThenticate to assess for potential overlap in prior publication.